Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.
The company scraps nemvaleukin after the latest failure, of Artistry-6.
TLX101 follows Ipax-1 with an apparent success in an academic trial.
J&J's new anti-ENPP3 ADC appears – and then disappears – from a clinical study listing.
Boehringer discontinues brigimadlin while others continue to struggle.
Meanwhile, Akeso challenges Moderna and BioNTech with an mRNA neoantigen play.
